Literature DB >> 16987306

Impact of alternative interventions on changes in generic dispensing rates.

A James O'Malley1, Richard G Frank, Atheer Kaddis, Barbara M Rothenberg, Barbara J McNeil.   

Abstract

OBJECTIVES: To evaluate the effectiveness of four alternative interventions (member mailings, advertising campaigns, free generic drug samples to physicians, and physician financial incentives) used by a major health insurer to encourage its members to switch to generic drugs.
METHODS: Using claim-level data from Blue Cross Blue Shield of Michigan, we evaluated the success of four interventions implemented during 2000-2003 designed to increase the use of generic drugs among its members. Around 13 million claims involving seven important classes of drugs were used to assess the effectiveness of the interventions. For each intervention a control group was developed that most closely resembled the corresponding intervention group. Logistic regression models with interaction effects between the treatment group (intervention versus control) and the status of the intervention (active versus not active) were used to evaluate if the interventions had an effect on the generic dispensing rate (GDR). Because the mail order pharmacy was considered more aggressive at converting prescriptions to generics, separate generic purchasing models were fitted to retail and mail order claims. In secondary analyses separate models were also fitted to claims involving a new condition and claims refilled for preexisting conditions.
RESULTS: The interventions did not appear to increase the market penetration of generic drugs for either retail or mail order claims, or for claims involving new or preexisting conditions. In addition, we found that the ratio of copayments for brand name to generic drugs had a large positive effect on the GDR.
CONCLUSIONS: The interventions did not appear to directly influence the GDR. Financial incentives expressed to consumers through benefit designs have a large influence on their switching to generic drugs and on the less-costly mail-order mode of purchase.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987306      PMCID: PMC1955290          DOI: 10.1111/j.1475-6773.2006.00579.x

Source DB:  PubMed          Journal:  Health Serv Res        ISSN: 0017-9124            Impact factor:   3.402


  2 in total

1.  Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Authors:  B Motheral; K A Fairman
Journal:  Med Care       Date:  2001-12       Impact factor: 2.983

2.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

  2 in total
  17 in total

1.  [Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurance and patients].

Authors:  Ghazaleh Gouya; Berthold Reichardt; Anja Bidner; Robert Weissenfels; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

2.  Regulated medical fee schedule of the Japanese health care system.

Authors:  Makoto Kakinaka; Ryuta Ray Kato
Journal:  Int J Health Care Finance Econ       Date:  2013-09-26

3.  Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs.

Authors:  Richard A Hansen; Jingjing Qian; Richard Berg; James Linneman; Enrique Seoane-Vazquez; Sarah K Dutcher; Saeid Raofi; C David Page; Peggy Peissig
Journal:  Pharmacotherapy       Date:  2017-03-20       Impact factor: 4.705

4.  Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs.

Authors:  Julie M Donohue; Michael A Fischer; Haiden A Huskamp; Joel S Weissman
Journal:  Health Serv Res       Date:  2008-05-13       Impact factor: 3.402

5.  Will We Ever Bend the Cost Curve in Healthcare?

Authors:  Ehsan U Syed
Journal:  Am Health Drug Benefits       Date:  2019 Jun-Jul

6.  Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs.

Authors:  Adam A Markovitz; Rob G Holleman; Timothy P Hofer; Eve A Kerr; Mandi L Klamerus; Jeremy B Sussman
Journal:  Health Serv Res       Date:  2017-12       Impact factor: 3.402

7.  Comparison of Outcomes Following a Switch From a Brand to an Authorized Versus Independent Generic Drug.

Authors:  R A Hansen; J Qian; R L Berg; J G Linneman; E Seoane-Vazquez; S Dutcher; S Raofi; C D Page; P L Peissig
Journal:  Clin Pharmacol Ther       Date:  2017-10-10       Impact factor: 6.875

Review 8.  Influencers of generic drug utilization: A systematic review.

Authors:  Jennifer N Howard; Ilene Harris; Gavriella Frank; Zippora Kiptanui; Jingjing Qian; Richard Hansen
Journal:  Res Social Adm Pharm       Date:  2017-08-04

9.  Patients' perceptions of generic medications.

Authors:  William H Shrank; Emily R Cox; Michael A Fischer; Jyotsna Mehta; Niteesh K Choudhry
Journal:  Health Aff (Millwood)       Date:  2009 Mar-Apr       Impact factor: 6.301

10.  Is there a relationship between patient beliefs or communication about generic drugs and medication utilization?

Authors:  William H Shrank; Suzanne M Cadarette; Emily Cox; Michael A Fischer; Jyotsna Mehta; Alan M Brookhart; Jerry Avorn; Niteesh K Choudhry
Journal:  Med Care       Date:  2009-03       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.